BMS-777607: Selective c-Met Inhibitor for Cancer and Platelet Models

Executive Summary: BMS-777607 is a highly selective, orally bioavailable ATP-competitive inhibitor targeting c-Met, Axl, Ron, and Tyro3 kinases, with nanomolar IC₅₀ values and over 40-fold selectivity against off-target kinases (APExBIO). It robustly impairs c-Met autophosphorylation in vitro and inhibits tumor metastasis in vivo without detectable systemic toxicity. The molecule accelerates megakaryocyte maturation in hiPSC-derived platelet protocols, reducing time and cost of production (Yue et al., 2026). BMS-777607 is recommended for research into MET signaling pathway inhibition, cancer metastasis, and advanced stem cell modeling.

Biological Rationale

The c-Met receptor tyrosine kinase is a critical regulator of cell proliferation, survival, motility, and invasion. Aberrant c-Met signaling is well-established in various malignancies, including prostate, lung, and breast cancers, where it drives tumor progression and metastasis (see BMS-777607: Redefining Selective MET Kinase Inhibition). Selective inhibition of c-Met and related kinases (Axl, Ron, Tyro3) is essential for dissecting MET-dependent pathways and developing targeted therapies. Recent studies also implicate MET signaling in megakaryocyte maturation, linking cancer biology and stem cell-derived platelet production (Yue et al., 2026).

Mechanism of Action of BMS-777607

BMS-777607 is an ATP-competitive inhibitor with high affinity for the MET kinase family. The compound blocks the autophosphorylation of c-Met, thereby disrupting downstream signaling cascades involved in proliferation, migration, and survival. It exhibits IC₅₀ values of 3.9 nM for c-Met, 1.1 nM for Axl, 1.8 nM for Ron, and 4.3 nM for Tyro3, with approximately 40-fold selectivity over kinases such as Lck, VEGFR-2, and TrkA/B, and over 500-fold selectivity compared to other kinases (APExBIO). Mechanistically, in cancer cells, BMS-777607 impedes MET-dependent tumorigenic processes. In stem cell-derived platelet models, it enhances megakaryocyte polyploidization, promoting the generation of more mature, functional platelets (BMS-777607: c-Met Inhibitor Enhances Stem Cell Platelet Protocols).

Evidence & Benchmarks

• BMS-777607 abolishes basal c-Met autophosphorylation in highly metastatic murine KHT cells at 10 μM in vitro, indicating potent MET signaling pathway inhibition (APExBIO).
• In vivo, oral administration at 25 mg/kg/day in mice with KHT xenografts reduces lung tumor nodules by 28.3% without apparent systemic toxicity (APExBIO).
• BMS-777607 demonstrates approximately 40-fold selectivity over Lck, VEGFR-2, and TrkA/B, and over 500-fold versus other receptor and non-receptor kinases (APExBIO).
• Megakaryocyte maturation and platelet yield from hiPSC-derived protocols are significantly enhanced with BMS-777607 supplementation, as demonstrated by increased polyploidy and shortened differentiation time (Yue et al., 2026).
• Protocols using BMS-777607 report a 58.3% reduction in platelet production costs and yield 14.9 platelets per iPSC (Yue et al., 2026).

For further context, this article details troubleshooting and reproducibility strategies, while this protocol-focused resource emphasizes cost-effectiveness and scaling, which are directly built upon here by integrating cross-domain efficacy evidence.

Applications, Limits & Misconceptions

BMS-777607 is validated for use in cancer metastasis models, particularly for studying MET signaling pathway inhibition in solid tumors and for dissecting apoptosis and metastasis suppression mechanisms. In stem cell research, it supports efficient differentiation of hiPSC-derived megakaryocytes, improving both platelet yield and function. The compound is intended solely for laboratory research.

Common Pitfalls or Misconceptions

• BMS-777607 is not approved for clinical, diagnostic, or therapeutic use and must not be administered to humans or animals outside controlled research protocols.
• The compound is insoluble in water and ethanol; DMSO is required for stock preparation at ≥25.65 mg/mL, with warming and ultrasonic shaking recommended (APExBIO).
• Stock solutions should be stored at -20°C and are not recommended for long-term storage once dissolved; degradation may affect potency.
• Off-target effects at high concentrations (>10 μM) or prolonged exposure have not been systematically ruled out across all cell types; always titrate for new applications.
• Not all cancer subtypes or stem cell lines will respond equally due to intrinsic pathway differences.

Workflow Integration & Parameters

BMS-777607 (A5703, APExBIO) is formulated as a solid compound with a molecular weight of 512.89 g/mol and chemical formula C₂₅H₁₉ClF₂N₄O₄. For optimal solubility, dissolve in DMSO, warm to 37°C, and use ultrasonic shaking as needed. The compound is shipped on blue ice and is intended solely for scientific research.

Protocol Parameters

• Solubility: Dissolve in DMSO at concentrations ≥25.65 mg/mL. Insoluble in water and ethanol. Warming to 37°C and ultrasonic shaking is recommended for rapid dissolution.
• Storage: Store solid at -20°C. Once dissolved in DMSO, use within short timeframes; do not store long-term.
• In vitro use: Abolish c-Met autophosphorylation in KHT cells with 10 μM treatment (APExBIO).
• In vivo dosing (mouse): 25 mg/kg/day by oral administration to achieve significant tumor reduction without systemic toxicity.
• Platelet differentiation: Supplement optimized hiPSC-to-megakaryocyte protocols with BMS-777607 to accelerate polyploidization and boost yield (Yue et al., 2026).
• Shipping: Blue ice required for small molecules; avoid repeated freeze-thaw cycles.

For additional troubleshooting and detailed workflows, see the BMS-777607: c-Met Inhibitor Enhances Stem Cell Platelet Protocols, which complements this article by emphasizing experimental maturation endpoints.

Conclusion & Outlook

BMS-777607 is a validated research tool for dissecting MET signaling and advancing both cancer and stem cell-derived platelet models. By leveraging its selectivity and efficacy, researchers can improve cancer metastasis studies and establish scalable, cost-effective platelet production platforms. Future directions include expanding its utility across additional hiPSC lines and tumor models, though its use remains confined to preclinical research according to current evidence (Yue et al., 2026). The integration of BMS-777607 into standard protocols is anticipated to streamline workflows and yield reproducible, high-fidelity data for translational research.